U.S. army identifies 6 critical research targets for improving outcomes in traumatic brain injury
The U.S. Department of Defense funds more than 500 neurotrauma research projects totaling over $700 million. Yet there remains a large unmet medical need for effective treatments of traumatic brain injury (TBI), a major cause of disability and mortality. The U.S. Army's new strategic research plan for developing improved drug therapies for TBI is published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Journal of Neurotrauma website.
The U.S. Army Medical Research and Materiel Command (USAMRMC) established the Neurotrauma Pharmacology Workgroup to develop a strategic research plan that identifies the most critical research priority areas with the goal of improving patient outcomes after TBI.
The Workgroup's report, "Pharmacotherapy of Traumatic Brain Injury: State of the Science and the Road Forward, Report of the Department of Defense Neurotrauma Pharmacology Workgroup," was coauthored by Ramon Diaz-Arrastia and Kimbra Kenney, Uniformed Services University of the Health Sciences (Bethesda, MD); Patrick Kochanek, University of Pittsburgh School of Medicine (PA); Peter Bergold, SUNY Downstate Medical Center (Brooklyn, NY); Christine Marx, Duke University Medical Center and Durham VA Medical Center (NC); Jamie Grimes, Defense and Veterans Brain Injury Center (Silver Spring, MD); Yince Loh, Madigan Army Medical Center (Tacoma, WA); Gina Adam, Kenneth Curley, and Wanda Salzer, U.S. Army MRMC (Ft. Detrick, MD); and Devon Oskvig (Rockville, MD).
John T. Povlishock, PhD, Editor-in-Chief of Journal of Neurotrauma and Professor, VCU Neuroscience Center, Medical College of Virginia, Richmond, notes that "although some of the themes advanced in this manuscript are not entirely new, the report helps to refocus current thought on those most critical research priority areas in the field of TBI pharmacological intervention. Additionally, the accompanying text addressing the current state of preclinical and clinical drug assessment will be an interesting read for all involved in this field of discovery."